학술논문
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study
Document Type
Artikel
Author
Source
Cerebrovascular diseases (Basel, Switzerland). 27(5):509-518
Subject
Language
English
English
English
ISSN
1421-9786